معرفی
Harri Itkonen is an Associate Professor in the Department of Clinical Molecular Biology at the University of Oslo. His research focuses on cancer biology, particularly prostate and breast cancer, with an emphasis on metabolic pathways, epigenetic regulation, and therapeutic targets. He investigates how enzymes like O-GlcNAc transferase and CDK9 influence cancer cell survival and drug resistance.
Key areas of research include the role of CDK7 and CDK9 in castration-resistant prostate cancer, the metabolic adaptations of cancer cells under stress, and the interplay between androgen signaling and oncogenes like MYC. His work bridges molecular mechanisms with translational applications, aiming to identify novel therapeutic strategies.
Itkonen has contributed to over 20 peer-reviewed articles since 2013, spanning topics such as lipid metabolism in cancer, chromatin alterations driven by bromodomain proteins, and the impact of O-GlcNAc modification on tumor suppressor genes. His studies frequently utilize cell culture models and molecular biology techniques to dissect complex signaling networks.
